Clinical Trials
5
Active:3
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (60.0%)Phase 1
1 (20.0%)Phase 2
1 (20.0%)A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
Phase 3
Active, not recruiting
- Conditions
- Human Papillomavirus Infection
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 1260
- Registration Number
- NCT06207175
- Locations
- 🇮🇩
University of Muhammadiyah Malang Hospital, Malang, Indonesia
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Phase 2
Completed
- Conditions
- Human Papilloma Virus Infection
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 780
- Registration Number
- NCT05694728
- Locations
- 🇨🇳
CDC, Jiangsu Province, Nanjing, Jiangsu, China
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Phase 1
Completed
- Conditions
- Human Papillomavirus Infection
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 160
- Registration Number
- NCT05680454
- Locations
- 🇨🇳
CDC, Jiangsu Province, Nanjing, Jiangsu, China
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
Phase 3
Active, not recruiting
- Conditions
- Human Papillomavirus Infection
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 12000
- Registration Number
- NCT05668572
- Locations
- 🇨🇳
CDC, Guangdong Provinc, Guangzhou, Guangdong, China
🇨🇳CDC, Jiangsu Province, Nanjing, Jiangsu, China
🇨🇳CDC, Shanxi Province, Taiyuan, Shanxi, China
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Phase 3
Active, not recruiting
- Conditions
- Human Papillomavirus Infection
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 2750
- Registration Number
- NCT05662020
- Locations
- 🇨🇳
Yunnan Center for Disease Prevention and Control, Kunming, Yunnan, China
News
No news found